ClinicalTrials.gg
CompletedNCT02851797Updated Feb 2, 2023Results posted

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

A Phase 3 interventional study of givinostat and placebo in Duchenne Muscular Dystrophy, sponsored by Italfarmaco. Completed at 42 sites in 11 countries. Open to male participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-02-02.

Sponsored by Italfarmaco · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
179
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 232 studies in Muscular Dystrophy, Duchenne with a site in United States — 34 open to participants now, 60 under way, 8 of them phase 3. Muscular Dystrophy, Duchenne · United States.

Enrollment
13th of 171
179 · median 25
Started
2017
with 10 others
Phase 3
32 of 232
3 open now
Registered
106th of 232
by date

Among the 232 studies in Muscular Dystrophy, Duchenne with a site in United States, this one is the 13th largest by enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2017, is one of 32 in phase 3, and was the 106th registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

34 of the 232 studies in Muscular Dystrophy, Duchenne with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 6 Years to 17 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Muscular Dystrophy, Duchenne with a site in United States, or all of them as a file.
02

Study summary

Primary Objective

The primary objective of the study was to establish the effects of givinostat versus placebo administered chronically over 18 months to slow disease progression in ambulant DMD subjects.

Secondary Objectives

The secondary objectives of this study were:

  • To assess the safety and tolerability of givinostat versus placebo administered chronically in DMD subjects
  • To evaluate the PK profile of givinostat administered chronically in DMD subjects
  • To evaluate the impact on quality of life (QoL) and activities of daily living of givinostat versus placebo administered chronically.
Read the detailed description

This was a phase 3, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant subjects with DMD. This study included ambulant male paediatric subjects aged ≥ 6 years at baseline affected by DMD.

A total of 179 male ambulant subjects was randomized 2:1 (givinostat: placebo).

Subjects were stratified for their concomitant use of steroids in 4 strata:

  1. Deflazacort daily regimen
  2. Deflazacort intermittent regimen
  3. Other steroids daily regimen
  4. Other steroids intermittent regimen. The study duration was planned to be 19 months.

Givinostat or placebo oral suspension (10 mg/mL) was administered orally as 2 oral doses daily while the subject were in fed state, according to the child's weight.

Study drug should have been permanently stopped if any of the following occurred:

  • severe drug-related diarrhoea;
  • any drug-related Serious Adverse Event;
  • QTcF >500 msec;
  • platelets count ≤50 x 10\^9/L.
  • white blood cells ≤2.0 x 10\^9/L
  • hemoglobin ≤8.0 g/dL

Study drug should have been temporarily stopped if any of the following occurred:

  • moderate or severe diarrhoea.
  • platelets count \<75 x 10\^9/L but >50 x 10\^9/L (the treatment should been temporarily stopped and a platelets count was to be performed and re-tested until platelets normalized);
  • white blood cell \<3.0 x 10\^9/L but >2.0 x 10\^9/L (the treatment should be temporarily stopped and white blood cells had to be measured by 1 week and re-tested until white blood cells normalized);
  • hemoglobin \<10.0 g/dL but > 8.0 g/dL (the treatment should be temporarily stopped and hemoglobin had to be measured by 1 week and re-tested until hemoglobin normalized);
  • Triglycerides >300 mg/dL (3.42 mmol/L) in fasting condition (the treatment should be temporarily stopped and triglycerides measured every 2 weeks until triglycerides returned to levels below 300mg/dL (3.42 mmol/L)

In case the study drug was temporarily stopped, the study drug could be resumed at a level 20% smaller than the one at which the Adverse Event leading to temporary stop occurred, once platelets and/or white blood cell and/or hemoglobin normalized and/or triglycerides returned to levels below 300 mg/dL (3.42 mmol/L) or diarrhoea was mild.

In addition, in case a subject had a consistent (e.g., at least 2 consecutive evaluations) platelets count ≤150 x 10\^9/L and didn't meet the stopping criteria for platelets, the Investigator should have to reduce the dose by 20% of the current dose.

Only one dose reduction was allowed during the treatment period.

This trial design a single planned interim analysis. The interim was governed by an IDMC in order to solely assess futility.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Dystrophy
  • DMD
  • Givinostat
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are an ambulant male aged ≥6 years at randomisation with DMD characteristic clinical symptoms or signs (e.g., proximal muscle weakness, Gowers' maneuver, elevated serum creatinine kinase level) already present at screening;
  2. Have DMD diagnosis confirmed by genetic testing;
  3. Are able to give informed assent and/or consent in writing signed by the subject and/or parent/legal guardian (according to local regulations);
  4. Are able to complete 2 Four Stairs Climb test (4SC) screening assessments; the results of these tests must be within ±1 second of each other;
  5. Have the mean of 2 screening 4SC assessments ≤8 seconds;
  6. Have time to rise from floor between ≥3 and \<10 seconds at screening
  7. Have manual muscle testing (MMT) of quadriceps at screening Grade ≥- 3;
  8. Have used systemic for a minimum of 6 months immediately prior to the start of study treatment, with no significant change in corticosteroids type or dosage or dosing regimen (excluding changes related to body weight change) for a minimum of 6 months immediately prior to start of study treatment and a reasonable expectation that dosage and dosing regimen will not change significantly for the duration of the study.
  9. Subjects must be willing to use adequate .

Exclusion criteria

Exclusion Criteria:

  1. Have exposure to another drug within 3 months prior to the start of study treatment;
  2. Have exposure to idebenone within 3 months prior to the start of study treatment;
  3. Have exposure to any dystrophin restoration product (e.g., Ataluren, Exon skipping) within 6 months prior to the start of study treatment;
  4. Use of any pharmacologic treatment, other than , that might have had an effect on muscle strength or function within 3 months prior to the start of study treatment (e.g., growth hormone); Vitamin D, calcium, and any other supplements will be allowed as long as their intake has been stable for 3 months prior to the start of study treatment; Testosterone will also be allowed if it is used as a replacement therapy for the treatment of delayed puberty, and testosterone dose and regimen have been stable for at least 6 months and circulating testosterone levels are within the normal ranges for the subject's age;
  5. Have surgery that might have an effect on muscle strength or function within 3 months before study entry or planned surgery at any time during the study;
  6. Loss of ≥30 degrees of plantar flexion from the normal range of movement at the ankle joint due to contracture (i.e. fixed loss of more than 10 degrees of plantar flexion from plantigrade, assuming normal range of dorsiflexion of 20 degrees;
  7. Change in contracture treatment such as serial casting, contracture control devices, night splints, stretching exercises (passive, active, self) within 3 months prior to enrollment, or expected need for such intervention during the study;
  8. Have presence of other disease, which, in the Investigator's opinion, could adversely affect the safety of the subject, making it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results;
  9. Have a diagnosis of other uncontrolled neurological diseases or presence of relevant uncontrolled somatic disorders that are not related to DMD;
  10. Have count at screening \< Lower Limit of Normal (LLN);
  11. Have symptomatic cardiomyopathy or heart failure ( Class III or IV) or \<50% at screening;
  12. Have a current or history of liver disease or impairment;
  13. Have inadequate renal function, as defined by serum Cystatin C >2 x the (ULN);
  14. Have Triglycerides > 300 mg/dL (3.42 mmol/L) in fasting condition at screening visit;
  15. Have a positive test for surface antigen, antibody, or at screening15.
  16. Have a baseline >450 msec, or history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, or family history of long QT syndrome);
  17. Have a psychiatric illness/social situations rendering the potential subject unable to understand and comply with the muscle function tests and/or with the study protocol procedures;
  18. Have any to the components of study medication;
  19. Have a sorbitol intolerance or sorbitol malabsorption, or have the hereditary form of fructose intolerance.
  20. Have to MRI or MRS (e.g., claustrophobia, metal implants, or seizure disorder).

At the discretion of the Investigator, subjects not meeting inclusion/exclusion criteria may be re-screened twice with an interval of at least 3 months between assessments.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
179 participants (actual)

Study arms

  • Active comparator
    givinostat

    Givinostat oral suspension (10 mg/mL) twice daily

    Drug: givinostat

  • Placebo comparator
    placebo

    Placebo oral suspension (10 mg/mL) twice daily

    Drug: placebo

Interventions

  • The oral suspension of givinostat (10 mg/mL) was to be dosed in fed condition as described below: Givinostat or placebo starting dose * \> or =10 and \< 12.5 kg of weight: 13.3 mg bid = 1.3 ml oral suspension bid * \> or =12.5 and \< 20 kg: 16.7 mg bid =1.7 ml oral suspension bid * \> or = 20 and \< 25 kg: 20 mg bid = 2.0 ml oral suspension bid * \> or = 25 and \< 30 kg: 23.3 mg bid = 2.3 ml oral suspension bid * \> or = 30 and \< 40 kg: 26.7 mg bid = 2.7 ml oral suspension bid * \> or = 40 and \< 50 kg: 33.3 mg bid = 3.3 ml oral suspension bid * \> or = 50 and \< 60 kg: 36.7 mg bid = 3.7 ml oral suspension bid * \> or = 60 and \< 70 kg: 40 mg bid = 4 ml oral suspension bid * \> or = 70 kg: 46.7 mg bid = 4.7 ml oral suspension bid

    Also known as: ITF2357

  • Drugplacebo

    The oral suspension of placebo, manufactured to mimic givinostat, was to be dosed in fed condition as described for givinostat.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment

    The time (in seconds) to climb 4 standard-sized stairs is a TFT that represents stair-climbing ability. The test was evaluated by qualified functional evaluators (ie, physiotherapists) who were different from the site personnel who reviewed subjects' safety results. The test was performed in a standardised manner described in a specific site manual. Baseline 4SC was the measurement taken at the randomization assessment, unless this was missing, in which case baseline was taken as the last non missing value recorded prior to or on the date of first study treatment. The shorter the time, the better the outcome.

    Time frame: Baseline and 18 months

Secondary outcomes

  1. Mean Change From Baseline in Time to Rise From Floor After 18 Months of Treatment

    An analysis of time (in seconds) to rise from the floor by change from baseline at 18 months is presented for the Target Population in the ITT analysis set. The shorter the time, the better the outcome.

    Time frame: Baseline and 18 months

  2. Mean Change From Baseline in the Six-minute Walking Test (6MWT) After 18 Months of Treatment

    This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. The 6-Minute Walk Test is a useful measure of functional capacity targeted at people with at least moderately severe impairment. A modified version of the 6MWT recommended by American Thoracic Society (2002) for use in adults was performed. The longer the walked distance the better the outcome.

    Time frame: Baseline and 18 months

  3. Mean Change From Baseline in Total North Star Ambulatory Assessment (NSAA) Score After 18 Months of Treatment

    The total North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy (DMD). It is usually used to monitor the progression of the disease and treatment effects. The 17 items of the NSAA, ranging from standing to running 10 meters, were graded using the standard score card with each assessment rated as 0 - unable to achieve independently, 1 - modified method but achieves goal independent of physical assistance from another, or 2 - normal with no obvious modification of activity. This scale is ordinal with 0 as the minimum score (indicating full disfunctionality, i.e. the worst outcome) and with 34 as the maximum score indicating fully-independent function (the best outcome).

    Time frame: Baseline and 18 months

  4. Cumulative Loss of Function on the NSAA

    Subject cumulative number of failures across all postbaseline visits was the endpoint of interest for analysis. For each subject at each postbaseline visit, failure to perform each of the 17 items of the NSAA was assessed, where "failure" was defined as a score transition from 2 or 1 at baseline to 0 at the respective visit. The total number of failed items for the visit was calculated (maximum of 17 failed items per visit per subject). The subject's cumulative number of failures across all visits was the sum of the total failures at each postbaseline visit.

    Time frame: over 18 months

  5. Mean Change From Baseline of Muscle Strength Normalized Overtime

    The mean change of muscle strength normalized was evaluated by knee extension and elbow flexion normalized by subject weight, both measured by hand-held myometry (HHM).

    Time frame: Baseline and 18 months

  6. Mean Change From Baseline in Vastus Lateralis Muscle Fat Fraction (VL MFF) at 18 Months

    Vastus lateralis muscle fat fraction (VL MFF) was expressed as fat infiltration in this muscle. Fat infiltration was assessed by Magnetic Resonance (MRS).

    Time frame: Baseline and 18 months

  7. Number of Subjects Experiencing Treatment-emergent AEs (TEAEs), Serious AEs (SAEs), Mild TEAE Moderate TEAE, Severe TEAE

    Adverse Events are unfavorable changes in health, including abnormal laboratory findings, that occur in trial participants during the clinical trial or within a specified period following the trial. Serious Adverse Events include adverse events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.

    Time frame: Baseline through end of study, that is the end of 18° month

  8. Evaluation of Acceptability/Palatability of the Oral Suspension

    Acceptability and palatability of the oral suspension over time are presented. More in details, child perception of the medicine at the three timepoints hereunder specified; parent perception of the medicine based on the child's reaction at the same three timepoints; and parent problems administering the medication at the same timepoints are reported.

    Time frame: Week 4, EOS, early withdrawal

07

Results

Posted Feb 2, 2023

Participant flow

Within the overall population, a total of 118 subjects were enrolled in the givinostat group. A total of 61 subjects were enrolled in the placebo group.

Participant flow — Overall Study
MilestoneGivinostatPlacebo
Started11861
All enrolled subjects11861
Itt population11861
Safety set11861
Pk analysis set1170
Target population8139
Mr cohort7737
Completed11159
Not completed72
Withdrew: Withdrawal by subject42
Withdrew: Adverse event30

Outcome measures

PrimaryMean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment

The time (in seconds) to climb 4 standard-sized stairs is a TFT that represents stair-climbing ability. The test was evaluated by qualified functional evaluators (ie, physiotherapists) who were different from the site personnel who reviewed subjects' safety results. The test was performed in a standardised manner described in a specific site manual. Baseline 4SC was the measurement taken at the randomization assessment, unless this was missing, in which case baseline was taken as the last non missing value recorded prior to or on the date of first study treatment. The shorter the time, the better the outcome.

Time frame:
Baseline and 18 months
Reported as:
Least squares mean · seconds
Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment
secondsGivinostatPlacebo
Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment1.27 ± 0.0401.48 ± 0.058
Statistical analysis
  • Givinostat vs Placebo · ANCOVA · p = =0.0345 (LS Means, CIs, and p-values are obtained from ANCOVA model on change from baseline in 4SC at Month 18 with baseline values for: the above mentioned parameters as covariates, with steroid use and treatment group as independent classificat factors.) · Generalised least square mean ratio: 0.86 · 95% CI 0.745 to 0.989LS Means, CIs, and p-values are obtained from ANCOVA model on change from baseline in 4SC at Month 18 with baseline values for: the above mentioned parameters as covariates, with steroid use and treatment group as independent classificat factors.
SecondaryMean Change From Baseline in Time to Rise From Floor After 18 Months of Treatment

An analysis of time (in seconds) to rise from the floor by change from baseline at 18 months is presented for the Target Population in the ITT analysis set. The shorter the time, the better the outcome.

Time frame:
Baseline and 18 months
Reported as:
Least squares mean · seconds
Mean Change From Baseline in Time to Rise From Floor After 18 Months of Treatment
secondsGivinostatPlacebo
Mean Change From Baseline in Time to Rise From Floor After 18 Months of Treatment9.33 (5.821 to 12.838)12.61 (7.491 to 17.724)
Statistical analysis
  • Givinostat vs Placebo · ANCOVA · p = =0.3044 (See comment above) · Difference in least square means: -3.28 · 95% CI -9.573 to 3.018See comment above
SecondaryMean Change From Baseline in the Six-minute Walking Test (6MWT) After 18 Months of Treatment

This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. The 6-Minute Walk Test is a useful measure of functional capacity targeted at people with at least moderately severe impairment. A modified version of the 6MWT recommended by American Thoracic Society (2002) for use in adults was performed. The longer the walked distance the better the outcome.

Time frame:
Baseline and 18 months
Reported as:
Least squares mean · meters
Mean Change From Baseline in the Six-minute Walking Test (6MWT) After 18 Months of Treatment
metersGivinostatPlacebo
Mean Change From Baseline in the Six-minute Walking Test (6MWT) After 18 Months of Treatment-38.43 (-50.704 to -26.153)-48.38 (-66.288 to -30.482)
Statistical analysis
  • Givinostat vs Placebo · ANCOVA · p = =0.3723 (See comment above) · Difference in least square means: 9.96 · 95% CI -12.071 to 31.983See comment above
SecondaryMean Change From Baseline in Total North Star Ambulatory Assessment (NSAA) Score After 18 Months of Treatment

The total North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy (DMD). It is usually used to monitor the progression of the disease and treatment effects. The 17 items of the NSAA, ranging from standing to running 10 meters, were graded using the standard score card with each assessment rated as 0 - unable to achieve independently, 1 - modified method but achieves goal independent of physical assistance from another, or 2 - normal with no obvious modification of activity. This scale is ordinal with 0 as the minimum score (indicating full disfunctionality, i.e. the worst outcome) and with 34 as the maximum score indicating fully-independent function (the best outcome).

Time frame:
Baseline and 18 months
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Total North Star Ambulatory Assessment (NSAA) Score After 18 Months of Treatment
score on a scaleGivinostatPlacebo
Mean Change From Baseline in Total North Star Ambulatory Assessment (NSAA) Score After 18 Months of Treatment-2.66 (-3.563 to -1.759)-4.58 (-5.891 to -3.260)
Statistical analysis
  • Givinostat vs Placebo · ANCOVA · p = =0.0209 (Same comment as above) · Difference in least square means: 1.91 · 95% CI 0.295 to 3.533Same comment as above.
SecondaryCumulative Loss of Function on the NSAA

Subject cumulative number of failures across all postbaseline visits was the endpoint of interest for analysis. For each subject at each postbaseline visit, failure to perform each of the 17 items of the NSAA was assessed, where "failure" was defined as a score transition from 2 or 1 at baseline to 0 at the respective visit. The total number of failed items for the visit was calculated (maximum of 17 failed items per visit per subject). The subject's cumulative number of failures across all visits was the sum of the total failures at each postbaseline visit.

Time frame:
over 18 months
Reported as:
Number · cumulative number of failures
Cumulative Loss of Function on the NSAA
cumulative number of failuresGivinostatPlacebo
Cumulative Loss of Function on the NSAA3.42 (2.692 to 4.334)5.56 (4.002 to 7.715)
Statistical analysis
  • Givinostat vs Placebo · negative binomial regression model · p = =0.0202 (same comment as above) · Ratio of cumulative failures: 0.61 · 95% CI 0.408 to 0.927A lower ratio indicates a greater reduction in cumulative loss of function across 18 months for givinostat compared with placebo. See also comment above.
SecondaryMean Change From Baseline of Muscle Strength Normalized Overtime

The mean change of muscle strength normalized was evaluated by knee extension and elbow flexion normalized by subject weight, both measured by hand-held myometry (HHM).

Time frame:
Baseline and 18 months
Reported as:
Least squares mean · Newtons/kg
Mean Change From Baseline of Muscle Strength Normalized Overtime
Newtons/kgGivinostatPlacebo
Overall knee extension-0.32 (-0.441 to -0.197)-0.50 (-0.681 to -0.328)
Overall elbow flexion-0.10 (-0.174 to -0.031)-0.19 (-0.292 to -0.085)
Statistical analysis
  • Givinostat vs Placebo · ANCOVA · p = =0.0902 (same comment as above) · Difference in least square means: 0.19 · 95% CI -0.030 to 0.401same comment as above
  • Givinostat vs Placebo · ANCOVA · p = =0.1818 (same comment as above) · Difference in least square means: 0.09 · 95% CI -0.041 to 0.213same comment as above
SecondaryMean Change From Baseline in Vastus Lateralis Muscle Fat Fraction (VL MFF) at 18 Months

Vastus lateralis muscle fat fraction (VL MFF) was expressed as fat infiltration in this muscle. Fat infiltration was assessed by Magnetic Resonance (MRS).

Time frame:
Baseline and 18 months
Reported as:
Least squares mean · percentage of fat
Mean Change From Baseline in Vastus Lateralis Muscle Fat Fraction (VL MFF) at 18 Months
percentage of fatGivinostatPlacebo
Mean Change From Baseline in Vastus Lateralis Muscle Fat Fraction (VL MFF) at 18 Months7.63 (6.098 to 9.172)10.56 (8.331 to 12.783)
Statistical analysis
  • Givinostat vs Placebo · ANCOVA · p = =0.0354 (Same comment as above) · Difference in least square means: -2.92 · 95% CI -5.641 to -0.204Same comment as above
SecondaryNumber of Subjects Experiencing Treatment-emergent AEs (TEAEs), Serious AEs (SAEs), Mild TEAE Moderate TEAE, Severe TEAE

Adverse Events are unfavorable changes in health, including abnormal laboratory findings, that occur in trial participants during the clinical trial or within a specified period following the trial. Serious Adverse Events include adverse events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.

Time frame:
Baseline through end of study, that is the end of 18° month
Reported as:
Count of participants · Participants
Number of Subjects Experiencing Treatment-emergent AEs (TEAEs), Serious AEs (SAEs), Mild TEAE Moderate TEAE, Severe TEAE
ParticipantsGivinostatPlacebo
Subjects with TEAE11257
Subjects with serious AE82
Subjects with mild AE6939
Subjects with moderate AE3817
Subjects with severe AE51
SecondaryEvaluation of Acceptability/Palatability of the Oral Suspension

Acceptability and palatability of the oral suspension over time are presented. More in details, child perception of the medicine at the three timepoints hereunder specified; parent perception of the medicine based on the child's reaction at the same three timepoints; and parent problems administering the medication at the same timepoints are reported.

Time frame:
Week 4, EOS, early withdrawal
Reported as:
Count of participants · Participants
Evaluation of Acceptability/Palatability of the Oral Suspension
ParticipantsGivinostatPlacebo
Child perception - week 4 - dislike very much3111
Child perception - week 4 - dislike a little2117
Child perception - week 4 - not sure3016
Child perception - week 4 - like a little1912
Child perception - week 4 - like very much113
Child perception - EOS - dislike very much217
Child perception - EOS - dislike a little2413
Child perception - EOS - not sure3416
Child perception - EOS - like a little1910
Child perception - EOS - like very much79
Child perception - early withdrawal - dislike very much10
Child perception - early withdrawal - dislike a little10
Child perception - early withdrawal - not sure20
Child perception - early withdrawal - like a little10
Child perception - early withdrawal - like very much00
Parent perception - week 4 - unpleasant5031
Parent perception - week 4 - not sure2810
Parent perception - week 4 - pleasant3518
Parent perception - EOS - unpleasant4214
Parent perception - EOS - not sure4022
Parent perception - EOS - pleasant2619
Parent perception - early withdrawal - unpleasant10
Parent perception - early withdrawal - not sure30
Parent perception - early withdrawal - pleasant10
Parent admin problems - week 4 - yes61
Parent admin problems - week 4 - no10758
Parent admin problems - EOS - yes50
Parent admin problems - EOS - no10255
Parent admin - early withdrawal - yes00
Parent admin - early withdrawal - no50

Adverse events

Collected over Throughout the study till the end of study (month 18, visit 15). More precisely at Visits 4 and 7 (month 1), at Visit 9 (month 2), at Visit 10 (month 3), at Visit 11 (month 6), at Visit 12 (month 9), at Visit 13 (month 12), at Visit 14 (month 15), at Visit 15 (EOS, month 18) and at the FUV (Follow-Up Visit to be performed after 4 weeks from the last dose of study drug (ie, 4 weeks ± 7 days)).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Givinostat0/118 (0%)8/118 (6.8%)112/118 (94.9%)
Placebo0/61 (0%)2/61 (3.3%)57/61 (93.4%)
Most frequent serious events
Most frequent serious events
EventGivinostatPlacebo
GastroenteritisInfections and infestations1/1182/61
Gastroenteritis viralInfections and infestations1/1180/61
InfluenzaInfections and infestations1/1180/61
Abdominal painGastrointestinal disorders1/1180/61
VomitingGastrointestinal disorders1/1180/61
Chest painGeneral disorders1/1180/61
Spinal fractureInjury, poisoning and procedural complications1/1180/61
DizzinessNervous system disorders1/1180/61
RashSkin and subcutaneous tissue disorders1/1180/61
Most frequent other events
Showing 10 of 37
Most frequent other events
EventGivinostatPlacebo
Platelet count decreasedInvestigations51/1189/61
DiarrhoeaGastrointestinal disorders43/11811/61
NasopharyngitisInfections and infestations31/11819/61
VomitingGastrointestinal disorders34/1188/61
HeadacheNervous system disorders28/11814/61
FallInjury, poisoning and procedural complications15/11813/61
Abdominal painGastrointestinal disorders25/1189/61
ThrombocytopeniaBlood and lymphatic system disorders19/1180/61
CoughRespiratory, thoracic and mediastinal disorders13/1189/61
Abdominal pain upperGastrointestinal disorders17/1187/61

Baseline characteristics

Number of Subjects Enrolled in Each Country (Overall Population).The all-enrolled subjects set included all subjects who were randomised to study treatment. The overall all-enrolled subjects set included all subjects in both the target and off-target populations (Group A + Group B) who were randomised to study treatment.

Age, Categorical
Age, Categorical(Participants)GivinostatPlaceboTotal
<=18 years11861179
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)GivinostatPlaceboTotal
Mean9.78 ± 2.0229.97 ± 2.0829.84 ± 2.039
Sex: Female, Male
Sex: Female, Male(Participants)GivinostatPlaceboTotal
Female000
Male11861179
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GivinostatPlaceboTotal
Hispanic or Latino9312
Not Hispanic or Latino10958167
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GivinostatPlaceboTotal
American Indian or Alaska Native000
Asian426
Native Hawaiian or Other Pacific Islander000
Black or African American303
White10657163
More than one race527
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)GivinostatPlaceboTotal
Canada9615
Netherlands538
Belgium639
United States241943
Italy241337
United Kingdom10313
Israel101
France9514
Serbia011
Germany13215
Spain17623
08

Study locations

42 sites
  • Neuromuscular Research Center UC Davis Department of Physical Medicine and Rehabilitation
    Davis, California 95817, United States
  • Rady Children's Hospital center - UCSD Department of Neuroscience
    San Diego, California 92123, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Connecticut Children's Medical Center - Division Neurology
    Hartford, Connecticut 06106, United States
  • Child Health Research Institute - Department of Pediatrics
    Gainesville, Florida 32610, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827, United States
  • MD Rare Disease Research, LLC
    Atlanta, Georgia 30318, United States
  • University of Iowa Children's Hospital
    Iowa City, Iowa 52242, United States
  • University of Minnesota - Department of Neurology
    Minneapolis, Minnesota 55455, United States
  • Washington University School of Medicine in St Louis - Department of Neurology
    Saint Louis, Missouri 63110, United States
  • Shriners Hospitals for Children
    Portland, Oregon 97239, United States
  • The Children's Hospital of Philadelphia Colket Translational Research Building
    Philadelphia, Pennsylvania 19104, United States
  • Virginia Commonwealth University Childrens Hospital of Richmond at Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • University Hospitals Leuven, Neuromuscular Reference Centre, Child Neurology
    Leuven, 03000, Belgium
  • Hospital de La Citadelle, Centre de Référence des Maladies Neuromuscolaires (CRMN)
    Liege, 04000, Belgium
  • Kinsmen Research Centre - Alberta Children's Hospital - Alberta Health Services
    Calgary, Alberta T3B6A8, Canada
  • The University of British Columbia, Children's and Womens Health Centre of BC Branch
    Vancouver, British Columbia V6H 3V4, Canada
  • Holland Bloorview Kids Rehabilitation Hospital
    Toronto, Ontario M4G1R8, Canada
  • CHU de Nantes - Hotel-Dieu - Hopital Nord Laennec, rez-de-chausse haut ail Ouest
    Nantes, 44093, France
  • Hopital Armand Trousseau I-Motion, Plateforme d'essais cliniques pédiatriques
    Paris, 75012, France
  • Universitatsklinikum Essen - Kinder und Jugendmedizin Neuropadiatrie
    Essen, 45122, Germany
  • Klinik un Policlinik fur Kinder und Jugendmedizin - Universitatsklinikum Hamburg Eppendorf
    Hamburg, 20246, Germany
  • Klinikum der Uniersitat Munchen - Campus Innenstadt
    Munchen, 80337, Germany
  • Institute of Neurology - Schneider Children's Medical Center of Israel Kaplan, 14
    Petach-Tikva, 4920235, Israel
  • IRCCS Istituto G.Gaslini, U.O.S.D. Centro Traslazionale di Miologia e Patologie Neurodegenerative
    Genova, 16147, Italy
  • A.O.U. Policlinico G. Martino, U.O.C. Neurologia e Malattie Neuromuscolari
    Messina, 98125, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, UOS di Neurologia Pediatrica
    Milano, 20122, Italy
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    Milano, 20133, Italy
  • Centro Clinico NeMO Fondazione Serena ONLUS Area SUD
    Milano, 20162, Italy
  • Ospedale Pediatrico Bambin Gesù, Malattie Neuromuscolari e Neurodegenerative
    Roma, 00146, Italy
  • Fondazione Policlinico Universitario "A.Gemelli", UOC Neuropsichiatria Infantile
    Roma, 00168, Italy
  • Leiden University Medical Center LUMC
    Leiden, ZH 2300 RC, Netherlands
  • Radboud University Medical Centre
    Nijmegen, 6500, Netherlands
  • Clinic of Neurology and Psychiatry for Children and Youth - Neurology Department Dr. Subotic 6a,
    Belgrade, 11000, Serbia
  • Hospital Sant Joan de Déu - Neuromuscular Pathology Unit
    Esplugues de Llobregat, Barcelona 08950, Spain
  • Hospital Materno-Infantil - Passeig de la Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, 41013, Spain
  • Hospital Universitari i Politécnic de la Fe - Servicio Neurologia
    Valencia, 46026, Spain
  • Alder Hey Children's Hospital NHS Trust
    Liverpool, L12 2AP, United Kingdom
  • UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre and MRC Centre for NMD
    London, EC1N 1EH, United Kingdom
  • The John Walton Muscular Dystrophy Research Centre - Freeman Hospital - Newcastle University - Institute of Genetic Medicine
    Newcastle upon Tyne, NE1 3BZ, United Kingdom
  • The Robert Jones and Agnes Hunt Orthopaedic Hospital - NHS Foundation Trust
    Oswestry, SY 10 7AG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Feb 2022, 56 months.

Results were first posted in Feb 2023, 11 months after primary completion.

Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 56 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2016
First posted
Aug 2, 2016
StartActual
Jun 6, 2017
Primary completionActual
Feb 22, 2022
CompletionActual
Feb 22, 2022
Results first posted
Feb 2, 2023
Last update
Feb 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02851797
Lead sponsor
Italfarmaco
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Aug 2, 2016
Start date
Jun 6, 2017
Primary completion
Feb 22, 2022
Completion
Feb 22, 2022
Results posted
Feb 2, 2023
Last update
Feb 2, 2023

Study contacts

Eugenio Mercuri, MD, PhD
principal investigator · Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Givinostat

Start the discussion